{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:13:40Z","timestamp":1792700020759,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T00:00:00Z","timestamp":1690675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T00:00:00Z","timestamp":1690675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s13555-023-00975-3","type":"journal-article","created":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T04:01:21Z","timestamp":1690689681000},"page":"2019-2030","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Early Discontinuation of Apremilast in Patients with Psoriasis and Gastrointestinal Comorbidities: Rates and Associated Risk Factors"],"prefix":"10.1007","volume":"13","author":[{"given":"Lana","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching An","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3636-3423","authenticated-orcid":false,"given":"Vardhaman","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaneh","family":"Kalirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Seigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,30]]},"reference":[{"issue":"6","key":"975_CR1","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"975_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29\u201339.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"975_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, Program fOr Evaluation of TYK2 inhibitor psoriasis second phase 3 trial. J Am Acad Dermatol. 2023;88(1):40\u201351.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"975_CR4","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003\u20132011. JAMA Dermatol. 2013;149(10):1180\u20135.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"975_CR5","first-page":"504","volume":"9","author":"SR Feldman","year":"2016","unstructured":"Feldman SR, Goffe B, Rice G, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9(9):504\u201313.","journal-title":"Am Health Drug Benefits"},{"issue":"12","key":"975_CR6","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","volume":"83","author":"P Schafer","year":"2012","unstructured":"Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583\u201390.","journal-title":"Biochem Pharmacol"},{"key":"975_CR7","unstructured":"FDA approves first oral treatment for all psoriasis severities [press release]. National Psoriasis Foundation, 2021. https:\/\/www.psoriasis.org\/advance\/fda-approves-first-oral-treatment-for-all-psoriasis-severities\/. Accessed 12 Dec 2022."},{"key":"975_CR8","unstructured":"Otezla [package insert]. Thousand Oaks, CA: Amgen Inc., 2021."},{"issue":"5","key":"975_CR9","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","volume":"70","author":"MG Lebwohl","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871\u201381.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"975_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37\u201349.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"975_CR11","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387\u201399.","journal-title":"Br J Dermatol"},{"issue":"2s","key":"975_CR12","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.12788\/j.sder.2018.011","volume":"37","author":"MA Menter","year":"2018","unstructured":"Menter MA, Armstrong AW, Gordon KB, Wu JJ. Common and not-so-common comorbidities of psoriasis. Semin Cutan Med Surg. 2018;37(2s):S48\u2013S51.","journal-title":"Semin Cutan Med Surg"},{"issue":"6","key":"975_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14168","volume":"33","author":"E Kapniari","year":"2020","unstructured":"Kapniari E, Dalamaga M, Papadavid E. Comorbidities burden and previous exposure to biological agents may predict drug survival of apremilast for psoriasis in a real-world setting. Dermatol Ther. 2020;33(6):e14168.","journal-title":"Dermatol Ther"},{"issue":"7","key":"975_CR14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/jdv.14832","volume":"23","author":"E Papadavid","year":"2018","unstructured":"Papadavid E, Rompoti N, Theodoropoulos K, Kokkalis G, Rigopoulos D. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018;23(7):1173\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"975_CR15","first-page":"479","volume":"25","author":"SR Feldman","year":"2018","unstructured":"Feldman SR, Tian H, Wang X, Germino R. Health care utilization and cost associated with biologic treatment patterns among patients with moderate to severe psoriasis: analyses from a large US claims database. J Manag Care Spec Pharm. 2018;25(4):479\u201388.","journal-title":"J Manag Care Spec Pharm"},{"issue":"7","key":"975_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/1346-8138.14943","volume":"46","author":"M Kishimoto","year":"2019","unstructured":"Kishimoto M, Komine M, Kamiya K, Sugai J, Ohtsuki M. Drug survival of apremilast in a real-world setting. J Dermatol. 2019;46(7):615\u20137.","journal-title":"J Dermatol"},{"key":"975_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jdin.2020.10.012","volume":"2","author":"T Graier","year":"2021","unstructured":"Graier T, Weger W, Sator PG, et al. Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: a registry analysis. JAAD Int. 2021;2:62\u201375.","journal-title":"JAAD Int"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00975-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-00975-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00975-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T19:07:39Z","timestamp":1692644859000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-00975-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,30]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["975"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-00975-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,30]]},"assertion":[{"value":"24 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Few formatting errors corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}